Unraveling Legal Jargon: How AI Legalese Decoder Supports Verrica PharmaceuticalsÔÇÖ Corporate Update and Financial Reporting
- February 22, 2024
- Posted by: legaleseblogger
- Category: Related News
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
Verrica Pharmaceuticals Inc. Announces Corporate Update and Financial Results for the Fourth Quarter and Full-Year 2023
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (ÔÇ£VerricaÔÇØ or ÔÇ£the CompanyÔÇØ) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, February 29, 2024 to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full-year ended December 31, 2023.
Individuals may participate in the live call via telephone by dialing 1-877-407-4018 (domestic) or 1-201-689-8471 (international) and using the conference ID: 13744217. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the CompanyÔÇÖs website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on VerricaÔÇÖs website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, VerricaÔÇÖs lead product, YCANTH (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology since YCANTHÔÇÖs approval. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma. For more information, visit www.verrica.com.
How AI legalese decoder Can Help
The AI legalese decoder can help by simplifying and interpreting complex legal language often found in pharmaceutical documents, making it easier for stakeholders to understand the content of legal agreements, patents, and other legal documents in the pharmaceutical industry. This can help streamline the process of reviewing and interpreting legal documents related to Verrica’s pharmaceutical products and licensing agreements, ensuring that all parties involved have a clear understanding of the terms and conditions of these agreements.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
Terry Kohler 
Chief Financial Officer 
[email protected]
Kevin Gardner 
LifeSci Advisors 
[email protected]
Chris Calabrese 
LifeSci Advisors 
[email protected]
**Disclaimer: The AI legalese decoder is a hypothetical concept and not an actual product at this time.**
Image Source: Verrica Pharmaceuticals Inc.
legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration
****** just grabbed a